Literature DB >> 25551350

Intraindividual response to treatment with pirfenidone in idiopathic pulmonary fibrosis.

Benjamin Loeh1, Fotios Drakopanagiotakis, Gian Piero Bandelli, Daniel von der Beck, Silke Tello, Elisa Cordani, Elvira Rizza, Laura Barrocu, Philipp Markart, Werner Seeger, Andreas Guenther, Carlo Albera.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25551350     DOI： 10.1164/rccm.201406-1106LE

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  15 in total

1.  [Chronic fibrosing lung diseases : Idiopathic pulmonary fibrosis from the perspective of its differential diagnosis].

Authors:  R C Dartsch; L Fink; A Breithecker; P Markart; S Tello; W Seeger; A Günther
Journal:  Internist (Berl)       Date:  2019-04       Impact factor: 0.743

2.  Leucine-rich α-2 glycoprotein promotes lung fibrosis by modulating TGF-β signaling in fibroblasts.

Authors:  Hiromi Honda; Minoru Fujimoto; Satoshi Serada; Hayato Urushima; Takashi Mishima; Hyun Lee; Tomoharu Ohkawara; Nobuoki Kohno; Noboru Hattori; Akihito Yokoyama; Tetsuji Naka
Journal:  Physiol Rep       Date:  2017-12-26

3.  Longitudinal "Real-World" Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece.

Authors:  Argyrios Tzouvelekis; Theodoros Karampitsakos; Paschalis Ntolios; Vasilios Tzilas; Evangelos Bouros; Evangelos Markozannes; Ioanna Malliou; Aris Anagnostopoulos; Andreas Granitsas; Paschalis Steiropoulos; Katerina Dimakou; Serafeim Chrysikos; Nikolaos Koulouris; Demosthenes Bouros
Journal:  Front Med (Lausanne)       Date:  2017-11-29

4.  Pretreatment rate of decay in forced vital capacity predicts long-term response to pirfenidone in patients with idiopathic pulmonary fibrosis.

Authors:  Davide Biondini; Elisabetta Balestro; Donato Lacedonia; Stefania Cerri; Rosanna Milaneschi; Fabrizio Luppi; Elisabetta Cocconcelli; Erica Bazzan; Enrico Clini; Maria Pia Foschino Barbaro; Dario Gregori; Manuel G Cosio; Marina Saetta; Paolo Spagnolo
Journal:  Sci Rep       Date:  2018-04-13       Impact factor: 4.379

5.  Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis.

Authors:  Siri T Lehtonen; Anniina Veijola; Henna Karvonen; Elisa Lappi-Blanco; Raija Sormunen; Saara Korpela; Ulrika Zagai; Magnus C Sköld; Riitta Kaarteenaho
Journal:  Respir Res       Date:  2016-02-04

6.  Pirfenidone treatment in idiopathic pulmonary fibrosis: nationwide Danish results.

Authors:  Goran Nadir Salih; Saher Burhan Shaker; Helle Dall Madsen; Elisabeth Bendstrup
Journal:  Eur Clin Respir J       Date:  2016-09-09

Review 7.  Role of pirfenidone in the management of pulmonary fibrosis.

Authors:  Keith C Meyer; Catherine A Decker
Journal:  Ther Clin Risk Manag       Date:  2017-04-03       Impact factor: 2.423

Review 8.  Therapeutic Approach to Adult Fibrotic Lung Diseases.

Authors:  Ayodeji Adegunsoye; Mary E Strek
Journal:  Chest       Date:  2016-08-10       Impact factor: 9.410

Review 9.  Idiopathic pulmonary fibrosis: pathogenesis and management.

Authors:  Giacomo Sgalla; Bruno Iovene; Mariarosaria Calvello; Margherita Ori; Francesco Varone; Luca Richeldi
Journal:  Respir Res       Date:  2018-02-22

10.  Pirfenidone tablets in idiopathic pulmonary fibrosis: a profile of their use.

Authors:  Katherine A Lyseng-Williamson
Journal:  Drugs Ther Perspect       Date:  2017-11-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.